4-factor prothrombin complex concentrate: Phase IIIb data

CSL's CSL Behring subsidiary reported data from an open-label Phase IIIb trial in 212 patients showing that 4-factor PCC met the co-primary endpoint of non-inferiority to plasma, the standard of care, in the adequacy of stopping an ongoing major bleed at 24 hours in patients requiring urgent...